<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213157</url>
  </required_header>
  <id_info>
    <org_study_id>OMU KAEK 2019/241</org_study_id>
    <nct_id>NCT04213157</nct_id>
  </id_info>
  <brief_title>Laparoscopic Partial Nephrectomy for cT1 Tumors</brief_title>
  <official_title>Evaluation Trifecta and Pentafecta Outcomes of Patients Underwent Laparoscopic Partial Nephrectomy for cT1 Renal Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsun Liv Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ondokuz Mayıs University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsun Liv Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate trifecta and pentafecta outcomes for laparoscopic partial
      nephrectomy (LNP) in patients with clinical T1N0M0 renal tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From November 2009 to August 2018 a total of 292 patients who underwent LPN by global
      ischemia were included in the study. The patients were allocated into two groups according to
      the tumor size; T1a (≤ 40 mm, n=215), T1b (41-70 mm, n=77). Demographics features, clinical
      tumor characteristics, intraoperative and postoperative outcomes were analyzed. A negative
      surgical margin, warm ischemia time (WIT) &lt; 20 min and no postoperative complications
      (Clavien-Dindo ≥ grade 3) were accepted to achieve the trifecta outcomes. Pentafecta has
      defined as trifecta criteria plus &gt;90% preservation of estimated glomerular filtration rate
      (eGFR) and no stage upgrade of chronic kidney disease 12 months after LPN. Univariable and
      multivariable analysis were used to identify factors predicting trifecta and pentafecta
      achievement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Actual">November 10, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Operation time</measure>
    <time_frame>at the end of the surgery</time_frame>
    <description>time from onset to complete of surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>at the end of the surgery</time_frame>
    <description>amount of bleeding during surgery (mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>warm ischemia time</measure>
    <time_frame>at the and of the surgery</time_frame>
    <description>The clamp time of the renal artery and vein which is required to complete tumor excision and renorrhaphy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>intraoperative complication</measure>
    <time_frame>at the end of the surgery</time_frame>
    <description>abnormal problmes that may be seen during surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative complication</measure>
    <time_frame>up to 3 months</time_frame>
    <description>abnormal problmes that may be seen after surgery and require additional intervention, treatment or follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functional outcomes</measure>
    <time_frame>up to 1 year postoperatively</time_frame>
    <description>serum creatinine level and estimated glomerular filtration rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>surigcal margin status</measure>
    <time_frame>up to 1 month postoperatively</time_frame>
    <description>presence or absence of tumors at the surgical margin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative decrease in renal function</measure>
    <time_frame>up to 1 year postoperatively</time_frame>
    <description>Comparison of preoperative and postoperative renal functions according to numerical and percentile values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CKD stage upgrading</measure>
    <time_frame>up to 1 year postoperatively</time_frame>
    <description>evaluation of preoperative and postoperative renal functions according to chronic kidney disease stages</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oncological outomes</measure>
    <time_frame>up to the last clinical control (months)</time_frame>
    <description>Presence or absence of local and/or distal tumor recurrence</description>
  </primary_outcome>
  <enrollment type="Actual">292</enrollment>
  <condition>Renal Cancer</condition>
  <condition>Renal Neoplasm</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Surgery</condition>
  <condition>Surgery--Complications</condition>
  <condition>Renal Functional Abnormality</condition>
  <condition>Oncology</condition>
  <condition>Oncology Problem</condition>
  <condition>Kidney Ischemia</condition>
  <condition>Kidney Injury</condition>
  <condition>Urologic Neoplasms</condition>
  <condition>Urologic Cancer</condition>
  <condition>Kidney Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Two hundred ninety-two patients who have a follow-up at least 12 months were included in
        the study. Those were allocated into two groups according to radiological tumor size; 215
        patients with tumor size ≤ 40 mm were included in group T1a and 77 patients with tumor size
        41-70 mm were included in group T1b.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Functioning contraleteral kidney

          -  Patients with complete data

          -  Patients with single renal tumor on the effected side

          -  Patients who approved the written consent form

        Exclusion Criteria:

          -  The patients with bilateral renal tumors (n=8, 16 LPNs)

          -  solitary kidney (n=8)

          -  horseshoe kidney (n=4)

          -  pelvic ectopic kidney (n=2)

          -  graft kidney (n=2)

          -  those with multiple renal tumors in a single kidney (n=3) or with &gt; 7 cm renal tumor
             (n=6)

          -  Patients who were operated on for colon cancer (n=4), prostate cancer (n=2),
             endometrial cancer (n=1) or adrenal mass (n=2) within the first year after LPN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saban Sarıkaya, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Ondokuz Mayıs University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ender Ozden, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Ondokuz Mayıs University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liv hospital samsun</name>
      <address>
        <city>Samsun</city>
        <zip>55020</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayıs University</name>
      <address>
        <city>Samsun</city>
        <zip>55030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Porpiglia F, Bertolo R, Amparore D, Fiori C. Margins, ischaemia and complications rate after laparoscopic partial nephrectomy: impact of learning curve and tumour anatomical characteristics. BJU Int. 2013 Dec;112(8):1125-32. doi: 10.1111/bju.12317. Epub 2013 Aug 13.</citation>
    <PMID>23937616</PMID>
  </results_reference>
  <results_reference>
    <citation>Minervini A, Siena G, Antonelli A, Bianchi G, Bocciardi AM, Cosciani Cunico S, Ficarra V, Fiori C, Fusco F, Mari A, Martorana G, Medica M, Mirone V, Morgia G, Porpiglia F, Rocco F, Rovereto B, Schiavina R, Simeone C, Terrone C, Volpe A, Carini M, Serni S; Members of the RECORd Project-LUNA Foundation. Open versus laparoscopic partial nephrectomy for clinical T1a renal masses: a matched-pair comparison of 280 patients with TRIFECTA outcomes (RECORd Project). World J Urol. 2014 Feb;32(1):257-63. doi: 10.1007/s00345-013-1155-7. Epub 2013 Sep 7.</citation>
    <PMID>24013181</PMID>
  </results_reference>
  <results_reference>
    <citation>Osaka K, Makiyama K, Nakaigawa N, Yao M. Predictors of trifecta outcomes in laparoscopic partial nephrectomy for clinical T1a renal masses. Int J Urol. 2015 Nov;22(11):1000-5. doi: 10.1111/iju.12893. Epub 2015 Aug 6.</citation>
    <PMID>26251228</PMID>
  </results_reference>
  <results_reference>
    <citation>Rais-Bahrami S, Romero FR, Lima GC, Kohanim S, Permpongkosol S, Trock BJ, Jarrett TW, Kavoussi LR. Elective laparoscopic partial nephrectomy in patients with tumors &gt;4 cm. Urology. 2008 Sep;72(3):580-3. doi: 10.1016/j.urology.2008.05.027. Epub 2008 Jul 16.</citation>
    <PMID>18632142</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>December 27, 2019</last_update_submitted>
  <last_update_submitted_qc>December 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsun Liv Hospital</investigator_affiliation>
    <investigator_full_name>Mehmet Necmettin Mercimek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>laparoscopic partial nephrectomy</keyword>
  <keyword>Trifecta</keyword>
  <keyword>Pentafecta</keyword>
  <keyword>Outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is not yet known if there will be a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

